

GIROLAMO PELAIA

Full Professor

pelaia@unicz.it

+1 (555) 555-5555

Cityville, USA

EDUCATION:

Degree in Medicine,

University of Reggio
Calabria (Medical School of
Catanzaro) with distinction
("summa cum laude")

Specialist in Respiratory Diseases,

University of Naples
"Federico II", Italy, with
distinction ("summa cum
laude").

CLINICAL EXPERIENCE:

Head of the Respiratory
Clinical Unit at the
University Hospital "Renato
Dulbecco" – Catanzaro,
Italy.

EXPERIENCE:

My research activity and scientific production primarily deal with the pathobiology of several respiratory disorders such as asthma, COPD, interstitial pulmonary diseases, respiratory failure and lung cancer, and also regard the molecular mechanisms underlying the therapeutic actions of the main drugs used for their treatments. In particular, my studies have focused on the role of "mitogen-activated protein kinases" in the signal transduction pathways activated by cytokines, growth factors and oxidative stress in primary cultures of human pulmonary endothelial cells, bronchial epithelial cells, lung cancer cell lines, and pulmonary fibroblasts. A major research interest concerns the activation and inhibition of these enzymes in cell death and proliferation, as well as in pharmacological modulation of lung inflammation and remodelling. I am also particularly interested in the recent advances referring to the biological therapies of severe asthma, with whom I am familiar since more than 18 years ago. In this regard, I am currently involved in several clinical trials, and I conduct clinical research according to good clinical practice. Furthermore, my group is actively engaged in real-life observational studies, assessing the clinical, functional and biological effects of currently available monoclonal antibodies targeting immunoglobulins E (IgE), interleukin-5 (IL-5) and its receptor, as well as the receptor of interleukins-4 (IL-4)/13 (IL-13) and the innate cytokine thymic stromal lymphopoietin (TSLP). In particular, we constantly evaluate in patients with severe asthma the impact of omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab on disease exacerbations, symptom control, airflow limitation, and inflammatory biomarkers. My scientific production comprehensively includes more than 180 papers published in international, peer-reviewed journals. .

- 1990-1992 - Post-doctoral fellow at Georgetown University, School of Medicine, Washington, D.C., U.S.A.
- 1996-2001 - Assistant Professor and Researcher (General and Pulmonary Pharmacology) at the Faculty of Pharmacy, University "Magna Græcia" of Catanzaro, Italy.
- 2002-2010 - Assistant Professor and Researcher (Respiratory Medicine) at the Medical School of "Magna Græcia" University - Catanzaro, Italy.
- 2011-2024 - Full Professor of Respiratory Medicine at the Medical School of "Magna Græcia" University - Catanzaro, Italy; Director of the Post-graduate Specialization School of Respiratory Diseases at the same University.